U.S. clinical trial for Zeiss microinvasive laser vision correction technology expands

Two years after its international launch, the small incision lenticule extraction (SMILE) procedure developed by Zeiss (Oberkochen, Germany) has been used to treat more than 80,000 eyes worldwide, and has received FDA approval for an expanded U.S. clinical trial. Currently, the procedure is established in Europe, China, and India.

Related: Ultrafast pulses for precision procedures

SMILE is a microinvasive method that offers improved predictability of the vision correction outcome without the need to create a corneal flap. It combines ultrafast laser technology and precise lenticule extraction: the company's VisuMax femtosecond laser creates a very thin disc of tissue (lenticule) inside the intact cornea, which can then be extracted through a small incision. An excimer laser is not required.

According to studies published in the American Journal of Ophthalmology and British Journal of Ophthalmology, post-surgery inflammation was less common, healing of the cornea was better, and dry-eye syndrome was reduced compared to LASIK.

In December 2013, the FDA granted approval to extend the trial to include myopia of up to -10.00 diopters. To date, a total of 255 patients have been treated at five centers in the U.S. Outside the U.S., there are more than 150 centers in 38 countries, with more than 300 surgeons performing the procedure.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Nanoparticles, NIR laser light combine to destroy cancer cells

A newly developed method that kills cancer cells using nanoparticles and near-infrared laser light.

Novel post-op patch delivers drug, gene, and light therapy to tumor sites

An adhesive patch can stick to a tumor site, either before or after surgery, to deliver a combination of drug, gene, and light therapy.

Low-level laser therapy is a potential noninvasive treatment for thrombocytopenia

Low-level laser therapy may offer a noninvasive, drug-free treatment for a potentially life-threatening bleeding disorder.

NIR light-activated nanoparticles can precisely target and treat tumors

Novel nanoparticles that use heat and near-infrared light can potentially target and ablate tumors with greater precision.

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World